{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:56:19Z","timestamp":1792785379792,"version":"4.5.0"},"reference-count":64,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"National Aeronautics and Space Administration","id":[{"id":"https:\/\/ror.org\/027ka1x80","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Toxicology"],"published-print":{"date-parts":[[2026,2,7]]},"DOI":"10.1080\/10408444.2026.2633422","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:14:19Z","timestamp":1776338059000},"page":"127-155","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A framework for assessing the safety of degraded pharmaceuticals for long-duration space missions - Part 2: framework application in four case studies"],"prefix":"10.1080","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-5580","authenticated-orcid":false,"given":"Andrey","family":"Massarsky","sequence":"first","affiliation":[{"name":"Stantec Consulting Services Inc.","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4821-9477","authenticated-orcid":false,"given":"Veneese J.B.","family":"Evans","sequence":"additional","affiliation":[{"name":"Stantec Consulting Services Inc.","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-9549","authenticated-orcid":false,"given":"Ernest S.","family":"Fung","sequence":"additional","affiliation":[{"name":"Stantec Consulting Services Inc.","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8288-5345","authenticated-orcid":false,"given":"Lisa G.L.","family":"Yang","sequence":"additional","affiliation":[{"name":"Stantec Consulting Services Inc.","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-0689","authenticated-orcid":false,"given":"Keegan L.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Stantec Consulting Services Inc.","place":["Denver, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-4177","authenticated-orcid":false,"given":"Amanda N.","family":"Buerger","sequence":"additional","affiliation":[{"name":"Stantec Consulting Services Inc.","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-9645","authenticated-orcid":false,"given":"Andrew","family":"Maier","sequence":"additional","affiliation":[{"name":"Stantec Consulting Services Inc.","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-1623","authenticated-orcid":false,"given":"John F.","family":"Reichard","sequence":"additional","affiliation":[{"name":"NASA Johnson Space Center","place":["Houston, USA"]},{"name":"Department of Environmental and Public Health Sciences, University of Cincinnati","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.129.495"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1218(93)90125-w"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115019"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.04.016"},{"issue":"12","key":"e_1_3_3_6_1","first-page":"20","article-title":"Managing excipient interactions","volume":"43","author":"Challenger CA.","year":"2019","unstructured":"Challenger CA. 2019. Managing excipient interactions. Pharm Technol. 43(12):20\u201323.","journal-title":"Pharm Technol"},{"key":"e_1_3_3_7_1","unstructured":"CompTox Chemicals Dashboard. 2024. CompTox chemicals dashboard v2.4.1. Available from: https:\/\/comptox.epa.gov\/dashboard\/"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2006.09.053"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41526-024-00414-3"},{"key":"e_1_3_3_10_1","unstructured":"DrugBank. 2025. Main website. Available from: https:\/\/go.drugbank.com\/"},{"key":"e_1_3_3_11_1","volume-title":"Azithromycin","author":"DrugBank","year":"2024","unstructured":"DrugBank. 2024a. Azithromycin. Canadian Institutes of Health Research. DrugBank Database; Accession Number: DB00207. Available from: https:\/\/go.drugbank.com\/drugs\/DB00207"},{"key":"e_1_3_3_12_1","volume-title":"Diclofenac","author":"DrugBank","year":"2024","unstructured":"DrugBank. 2024b. Diclofenac. Canadian Institutes of Health Research. DrugBank Database; Accession Number: DB00586. Available from: https:\/\/go.drugbank.com\/drugs\/DB00586"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-128x(01)00149-0"},{"key":"e_1_3_3_14_1","unstructured":"[FDA] U.S. Food and Drug Administration. 2012. Center for drug evaluation and research. Application Number: 204592Orig1s000. Pharmacology Review(s). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204592Orig1s000PharmR.pdf"},{"key":"e_1_3_3_15_1","unstructured":"[FDA] U.S. Food and Drug Administration. 2023. Guidance for industry M7(R2) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08162.x"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2005.02.016"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080236"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2021.112125"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1352497"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.030"},{"key":"e_1_3_3_22_1","unstructured":"[HRP] Human Research Program. 2024. Risk of ineffective or toxic medications during long-duration exploration spaceflight. Available from: https:\/\/humanresearchroadmap.nasa.gov\/Risks\/risk.aspx?i=177"},{"key":"e_1_3_3_23_1","unstructured":"[ICH] International Council for Harmonisation. 2017. ICH harmonised guideline: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuitcals to limit potential carcinogenic risk M7(R1) Step 4."},{"key":"e_1_3_3_24_1","unstructured":"[ICH] International Council for Harmonisation. 2023. ICH harmonised guideline: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7 (R2): final version International Council for Harmonisation."},{"key":"e_1_3_3_25_1","unstructured":"[ICH] International Council for Harmonisation. 2024. ICH Q3C (R9) guideline on impurities: guideline for residual solvents Step 5."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.01.030"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.08.053"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/npjmgrav.2016.8"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-6757(93)90080-u"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23925"},{"key":"e_1_3_3_31_1","unstructured":"Khan M Wotring VE. 2014. FDA comprehensive stability evaluation of three medications. Report for NASA by V.E. Wotring. Unpublished data."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp5003976"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1996.1076"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2010.10.025"},{"key":"e_1_3_3_35_1","unstructured":"Lhasa. 2024. Our solutions. Available from: https:\/\/www.lhasalimited.org\/solutions\/"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/02652049809008240"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20636"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1039\/C0MD00214C"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2025.2533943"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0782-9"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.21608\/bfsa.1983.102090"},{"key":"e_1_3_3_42_1","unstructured":"[OECD] Organisation for Economic Co-operation and Development. 2024a. The OECD QSAR Toolbox. Available from: https:\/\/www.oecd.org\/chemicalsafety\/risk-assessment\/oecd-qsar-toolbox.htm"},{"key":"e_1_3_3_43_1","unstructured":"[OECD] Organisation for Economic Co-operation and Development. 2024b. Test Guideline No. 442D. In\u00a0Vitro Skin Sensitisation. Available from: https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2022\/06\/test-no-442d-in-vitro-skin-sensitisation_g1g507d0\/9789264229822-en.pdf"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400083h"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.3797\/scipharm.1109-16"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002109900174"},{"key":"e_1_3_3_47_1","unstructured":"PubChem. 2024a. Azithromycin. national center for biotechnology information. pubchem compound summary for CID 447043 azithromycin. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/447043"},{"key":"e_1_3_3_48_1","unstructured":"PubChem. PubChem. Compound Summary for CID 3033 Diclofenac. Available from: 2024b. Diclofenac. National Center for Biotechnology Informationhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/3033"},{"key":"e_1_3_3_49_1","unstructured":"PubChem. PubChem. Compound Summary for CID 3446 Gabapentin. Available from: 2024c. Gabapentin. National Center for Biotechnology Informationhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/3446"},{"key":"e_1_3_3_50_1","unstructured":"PubChem. PubChem. Compound Summary for CID 5991 Ethinyl estradiol. Available from: 2024d. Ethinyl Estradiol. National Center for Biotechnology Informationhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5991"},{"key":"e_1_3_3_51_1","unstructured":"PubChem. PubChem. Compound Summary for CID 6230 Norethindrone. Available from: 2024e. Norethindrone. National Center for Biotechnology Informationhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6230"},{"key":"e_1_3_3_52_1","unstructured":"[PQRI] Product Quality Research Institute. 2021. Safety thresholds and best demonstrated practices for extractables and leachables in parenteral drug products. (Intravenous Subcutaneous and Intramuscular). Available from: https:\/\/pqri.org\/wp-content\/uploads\/2022\/03\/PQRI-PDP-Recommendation-2022.pdf"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41526-023-00271-6"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.3797\/scipharm.1301-24"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.20485"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1383-5742(01)00055-2"},{"key":"e_1_3_3_57_1","unstructured":"STopTox. 2024. STopToxAvailable from https:\/\/stoptox.mml.unc.edu\/"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.08.041"},{"key":"e_1_3_3_59_1","unstructured":"Voltaren. 2024. Voltaren Pain Gel. Available from: https:\/\/www.voltarengel.com\/arthritis-pain-gel\/"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2004.12.013"},{"key":"e_1_3_3_61_1","first-page":"75","article-title":"Impurities in drug products","volume":"5","author":"Waterman KC","year":"2004","unstructured":"Waterman KC, Adami RC, Hong JY. 2004. Impurities in drug products. Sep Sci Technol. 5:75\u201388.","journal-title":"Sep Sci Technol"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-011-9677-z"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seppur.2024.127375"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-011-9652-8"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23115"}],"container-title":["Critical Reviews in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408444.2026.2633422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10408444.2026.2633422","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408444.2026.2633422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:02:45Z","timestamp":1790964165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10408444.2026.2633422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,7]]}},"alternative-id":["10.1080\/10408444.2026.2633422"],"URL":"https:\/\/doi.org\/10.1080\/10408444.2026.2633422","relation":{},"ISSN":["1040-8444","1547-6898"],"issn-type":[{"value":"1040-8444","type":"print"},{"value":"1547-6898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itxc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itxc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}